Strategic Blueprint’s Genmab GMAB Stock Holding History

Strategic Blueprint’s Portfolio GMAB Stock Details GMAB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-52	Closed	-$2K	–	754
2021 Q2	$2K	Buy	+52	New	+$2.01K	﹤0.01%	1227

Other funds holding GMAB

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Strategic Blueprint's GMAB Position: Q3 2021 in Review

Strategic Blueprint sold out of Genmab (GMAB) in Q3 2021, closing a stake of 52 shares — an estimated $2K sold.

Strategic Blueprint first reported a position in GMAB in Q2 2021 and held it in 1 quarter. The position peaked at $2K in Q2 2021. 211 funds tracked by Wall St. Rank hold GMAB as of Q3 2021.

Strategic Blueprint reported no remaining Genmab position as of Q3 2021 after selling out during the quarter.
Strategic Blueprint sold 52 Genmab shares in Q3 2021, an estimated $2K.
Strategic Blueprint first reported a position in Genmab in Q2 2021 and held it in 1 quarter.
Strategic Blueprint's Genmab position peaked at $2K in Q2 2021.
211 funds tracked by Wall St. Rank held Genmab as of Q3 2021.

Based on Strategic Blueprint's 13F filing for Q3 2021, filed 12 Nov 2021.